Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invex TherapeuticsASX:IXC EV-to-OCF is -2.45 as of Jul. 18, 2026. The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, Invex Therapeutics ranks worse than 52.87% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Invex Therapeutics's Enterprise Value is A$2.92 Mil.
Invex Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-1.19 Mil. Therefore, Invex Therapeutics's EV-to-OCF for today is -2.45.
The historical rank and industry rank for Invex Therapeutics's EV-to-OCF or its related term are showing as below:
ASX:IXC'
s EV-to-OCF Range Over the Past 10 Years
Min: -2.77 Med: 0 Max: -2.77
Current: -2.77
During the past 6 years, the highest EV-to-OCF of Invex Therapeutics was -2.77. The lowest was -2.77. And the median was .
ASX:IXC's EV-to-OCF is ranked worse than 52.87% of 1411
companies
in the Biotechnology industry
Industry Median: -3.28
vs ASX:IXC: -2.77
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Invex Therapeutics's PE Ratio (TTM) for today is calculated as:
Invex Therapeutics's share price for today is A$0.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invex Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.012.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Invex Therapeutics EV-to-OCF Related Terms
Invex Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Invex Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Invex Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invex Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Invex Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Invex Therapeutics's EV-to-OCF falls into.
Invex Therapeutics's current Enterprise Value is A$2.92 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invex Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-1.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invex Therapeutics (ASX:IXC) has a EV-to-OCF of -2.45 as of Jul. 18, 2026. According to the industry distribution chart, Invex Therapeutics ranks #746 out of 1411 companies in the Biotechnology industry, placing it in the top 52.9%.
Is Invex Therapeutics' EV-to-OCF too high?
Invex Therapeutics' current EV-to-OCF is -2.45. Based on the distribution chart, Invex Therapeutics ranks #746 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint.
How does Invex Therapeutics' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Invex Therapeutics ranks #746 out of 1411 companies for EV-to-OCF. This places Invex Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Invex Therapeutics's current EV-to-OCF is -2.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current EV-to-OCF of -2.45. The current EV-to-OCF is -2.45. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current EV-to-OCF is -2.45 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IXC has been successfully added to your 
